Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
复制标题
DOI：
10.1016/j.vaccine.2006.04.068
复制
发表时间：
2006-07-07
期刊：
影响因子：
5.5
通讯作者：
Barr, Eliav
中科院分区：
文献类型：
--
作者：
Villa, Luisa L.;Ault, Kevin A.;Barr, Eliav
人乳头瘤病毒（HPV）感染可导致宫颈癌和生殖器疣。年轻女性（1106例）随机接受四价HPV（6/11/16/18型）L1病毒样颗粒（VLP）疫苗的三种制剂之一或两种安慰剂制剂之一。目的是评估基线HPV 6/11/16或18初治和既往感染受试者的疫苗安全性和免疫原性。所有三种制剂均具有高度免疫原性。在第2个月（第1次给药后），在基线时具有疫苗型抗体的女性中，疫苗诱导的抗HPV应答比基线初治女性中观察到的应答高12至26倍，这表明存在回忆应答。在最初的类似规模的下降之后，抗HPV应答达到平台，并在研究结束（3.0年）时保持稳定。未报告与疫苗相关的严重不良反应。(c)2006爱思唯尔有限公司保留所有权利。
Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naive and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were similar to 12- to 26-fold higher than those observed in baseline-naive women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported. (c) 2006 Elsevier Ltd. All rights reserved.